Literature DB >> 7714147

Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins.

E Giudice1, C Crisci, A Eshkol, R Papoian.   

Abstract

Gonadotrophin preparations extracted from post-menopausal urine are of low purity and the major protein components are not gonadotrophins. A study was undertaken to identify some of these non-gonadotrophin proteins present in the extracted human urinary gonadotrophin preparations that are commercially available, i.e. Humegon (Organon), HMG Massone (Massone), Metrodin (Serono), Metrodin HP (Serono), Pergonal (Serono) and Progonadyl (Elea). As revealed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie blue staining and Western blotting analysis, these products had electrophoretic protein profiles which differed in the amounts and species of proteins present. With the exception of Metrodin HP, all the other preparations tested contained tumour necrosis factor binding protein-I, transferrin, and immunoglobulin-related proteins. Some of the products contained in addition: urokinase, Tamm-Horsfall glycoprotein and epidermal growth factor. Recently, a highly purified human urinary follicle stimulating hormone (FSH) preparation (Metrodin HP) became available. In this preparation human FSH represents > 95% of the total proteins (approximately 10,000 IU of FSH/mg of protein). Metrodin HP was demonstrated to be the purest preparation tested, with none of the above-mentioned contaminants detected.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7714147     DOI: 10.1093/oxfordjournals.humrep.a138440

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Is infertility associated with childhood autism?

Authors:  Judith K Grether; Yinge Qian; Mary S Croughan; Yvonne W Wu; Michael Schembri; Loretta Camarano; Lisa A Croen
Journal:  J Autism Dev Disord       Date:  2013-03

2.  A randomized prospective cross-over study of highly purified follicle-stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in women aged 37-41 years.

Authors:  S Bassil; C Wyns; J Donnez
Journal:  J Assist Reprod Genet       Date:  2000-02       Impact factor: 3.412

Review 3.  Pharmacological interventions for the induction of ovulation.

Authors:  J A Collins; E G Hughes
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 4.  Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.

Authors:  Rogério de Barros F Leão; Sandro C Esteves
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

5.  Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin.

Authors:  Andrea F D Di Stefano; Antonio Rusca; Milko M Radicioni; Luca Loprete; Daniela Binelli; Giorgio Caccia; Barbara Cometti
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

6.  A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF).

Authors:  Carlo Alviggi; Alberto Revelli; Paola Anserini; Antonio Ranieri; Luigi Fedele; Ida Strina; Marco Massobrio; Nicola Ragni; Giuseppe De Placido
Journal:  Reprod Biol Endocrinol       Date:  2007-12-04       Impact factor: 5.211

Review 7.  A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology.

Authors:  Diego Ezcurra; Peter Humaidan
Journal:  Reprod Biol Endocrinol       Date:  2014-10-03       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.